Alzheimer’s disease (AD), a heterogeneous, neurodegenerative condition with an insidious onset and slow progression, is the leading cause of disability and morbidity as well as the sixth-leading cause of death in the United States. Diagnoses is often challenging, and multimodal imaging strategies and other novel and emerging biomarkers can aid in differential diagnosis. Currently only symptomatic therapies are available, but recent clinical trials investigating disease-modifying therapies (DMTs) that could slow or reverse the progression of AD have shown great promise.
CME Outfitters is pleased to offer accredited CME/CE activities providing expert-led education on the pathogenesis of AD, current diagnostic criteria and guidelines for AD management, recent advances in the development of AD biomarkers, and the latest clinical evidence on emerging therapies.
This Live and OnDemand webcast will feature interactive and lively discussion among specialists who treat patients with AD, with a focus on recognizing early-stage symptoms of AD, the potential role of emerging therapies in treating patients with early-stage AD, and integrating multimodal imaging strategies into the diagnostic process.
Please join expert faculty for this CMEO video webcast on best practices for diagnosing CIs.
A podcast on integrating cognitive testing into annual wellness visits for adults in order to gain early identification of cognitive impairment and initiating referral to a specialist.